UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) | February 25, 2009 |
WaferGen Bio-systems, Inc. |
(Exact name of registrant as specified in its charter) |
Nevada | 333-136424 | 20-3699764 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
Bayside Technology Center | ||
46531 Fremont Blvd. | ||
Fremont, CA | 94538 | |
(Address of principal executive offices) | (Zip Code) |
(510) 651-4450 |
(Registrant’s telephone number, including area code) |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On February 25, 2009, WaferGen Bio-systems, Inc. (the “Registrant”) issued a press release (the “Press Release”) with respect to data on the company’s SmartChip™ Real-Time PCR System presented on that day as part of a poster presentation (the “Poster”) at Cambridge Healthcare Institute’s 16th International Molecular Medicine Tri-Conference in San Francisco, California. The Press Release and the Poster are annexed as Exhibits 99.1 and 99.2 hereto and are hereby incorporated herein and made a part hereof.
The information in this Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Registrant specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. | Exhibit Description |
99.1 | Press Release dated February 25, 2009 |
99.2 | Poster: High-Density, Nano-Volume SmartChip™ System for Real-Time Gene Expression Analysis |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WaferGen Bio-systems, Inc. | |||
Date: February 25, 2009 | By: | /s/ Alnoor Shivji | |
Name: Alnoor Shivji | |||
Title: Chief Executive Officer and President | |||